Stay updated with breaking news from Both Ipsen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the CONTACT-01 study did not meet its primary endpoint of overall survival at the final analysis. CONTACT-01 is a phase 3 trial evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) versus docetaxel in p...
The trial did not meet its primary endpoint of overall survival (OS)The safety profile of the combination of cabozantinib and atezolizumab was consistent with the known safety profiles for each single agentThe clinical trial results will be presented at a future medical meetingPARIS--(BUSINESS WIRE)--Regulatory News...
The trial did not meet its primary endpoint of overall survival (OS) The safety profile of the combination of cabozantinib and atezolizumab was consistent with the known safety profiles for